AUTHOR=Hang Wie , Luo Jiayu , Wen Jianbo , Jiang Mingjun 

TITLE=The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review

JOURNAL=Frontiers in Surgery

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2022.898304

DOI=10.3389/fsurg.2022.898304

ISSN=2296-875X

ABSTRACT=<sec><title>Background</title><p>The relationship between systemic immune inflammation index (SII) and the prognosis of cancer has always been a subject of intense interest. However, the prognostic value of SII in non-small cell lung cancer (NSCLC) patients remains a controversial topic.</p></sec><sec><title>Objective</title><p>To evaluate the effect of SII index on prognosis of NSCLC.</p></sec><sec><title>Methods</title><p>We conducted a comprehensive search of PubMed, EMBASE, and the Cochrane Library databases to determine correlation between SII index, clinicopathological features, overall survival (OS), and progression-free survival (PFS). Odds ratio (ORs) and 95% confidence interval (CIs) were used to assess the connection between SII and clinicopathological parameters, and HRs and 95% CIs were used to assess the connection between SII and survival.</p></sec><sec><title>Results</title><p>Seventeen studies with 8,877 cases were included in the analysis. Compared with NSCLC patients with low SII level, patients with NSCLC with high SII level had a poor OS (HR = 1.75, 95% CI, 1.50–2.00; <italic>P</italic> &lt; 0.001) and had a poor PFS (HR = 1.61, 95% CI, 1.25–1.96; <italic>P</italic> &lt; 0.001). In addition, patients with higher pathological stage (II–III) had higher SII levels (OR = 2.32, 95% CI, 2.06–2.62; <italic>P</italic> &lt; 0.001).</p></sec><sec><title>Conclusions</title><p>The SII index is a promising prognostic biomarker for NSCLC and may help clinicians choose appropriate NSCLC treatments.</p></sec>